Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT06636240
Recruiting Not applicable

Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis

NCT06636240 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2025-03-17
Last updated
2025-05-25

Condition(s) studied

Atopic Dermatitis (Eczema)Atopic Dermatitis, Probiotics

Investigational drug(s) / intervention(s)

Mulberry fruit juiceMometasone furoate 0.1% cream

Mulberry fruit juice: Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including topical Mometasone furoate cream 0.1%

Mometasone furoate 0.1% cream: Standard therapy for atopic dermatitis including Mometasone furoate cream 0.1%

Study summary

This project proposes a randomized controlled human study to explore the prebiotic effects of consuming mulberry juice on atopic dermatitis in children and adolescents. The study aims to investigate the potential of mulberry fruit as a human prebiotic. This human study will recruit up to 120 participants from the Taipei Medical University Hospital (commissioned by the Ministry of Health and Welfare). Participants will be divided into experimental groups and a control group, with a 3-month intervention involving five clinical assessments and three stool collections. The goal is to compare the severity of atopic dermatitis, gut microbiota, and metabolite changes during the 6 days of mulberry juice consumption between the experimental and control groups.

This project will help establish mulberry fruit as a potential human prebiotic and adjunctive treatment for alleviating atopic dermatitis in children.

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 6 years and above (including 6 years) to less than 18 years (excluding 18 years) * The legal guardian has the ability to understand and is willing to sign the written informed consent document * Diagnosed by a physician according to the international Hanifin \& Rajka criteria for atopic dermatitis, with a confirmed diagnosis of more than six months Exclusion Criteria: * Allergic to berries, mulberries, fruits from the same family (such as figs), or similar chemical or biological components * Patients with immunodeficiency, including congenital or acquired immune disorders * Patients with immune-related diseases other than allergies, asthma, or allergic rhinitis, including malignancies, rheumatic diseases, lupus erythematosus, chronic liver diseases, cirrhosis, kidney diseases, diabetes, or asplenia * Individuals with other diseases or mental disorders that prevent them from complying with the intervention plan * Patients with Short Bowel Syndrome * Received oral or injectable antibiotics in the past month * Received immunomodulators, biologics, or oral/injectable steroids exceeding 2 mg/kg/day in the past three months * Underwent major surgery within 28 days before the study intervention (including the 28th day) or have not recovered from the side effects or complications of drug treatment/surgery from four weeks prior * Currently participating in other drug intervention studies * Currently experiencing systemic infection or unexplained fever (ear temperature greater than or equal to 38°C) * Pregnancy * Premature infants (born before 37 weeks, excluding 37 weeks) * Individuals with congenital diseases, nutritional or metabolic disorders, or keratinization disorders * Diagnosed with malignancies within the past five years.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Taipei Medical University-Shuang Ho Hospital New Taipei City Taiwan Recruiting
Taipei Medical University Shuang Ho Hospital New Taipei City Taiwan Not Yet Recruiting

More Taipei Medical University Shuang Ho Hospital trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06636240 on ClinicalTrials.gov ↗ ← All trials in Taiwan